INTRODUCTION
============

The worldwide incidence of congenital diaphragmatic hernia (CDH) is 1 in 4000 births.^[@ref1]^ The main feature of CDH is a defect in the diaphragm, which allows the intra-abdominal organs to migrate into the chest, preventing the lungs from growing normally due to the limited space and resulting in pulmonary hypoplasia. Pulmonary hypoplasia is accompanied by structural alterations of pulmonary vessel walls, which is thought to lead to pulmonary hypertension (PH).^[@ref2]^ Despite the recent progress, CDH is associated with a high rate of mortality rate (approximately 30% -- 40%).^[@ref3]^ In CDH, PH is the main cause of death during neonatal period.^[@ref4]^ After birth, the therapeutic strategies include high-frequency oscillatory ventilation, inhaled nitric oxide, extracorporeal membrane oxygenation, and the use of corticosteroids and/or surfactants to improve the function of the hypoplastic lungs in PH.^[@ref5],[@ref6],[@ref7]^ However, the optimal management of PH in CDH remains controversial.^[@ref5]^ Recently, as an antenatal surgical intervention for severe CDH, fetoscopic endoluminal tracheal occlusion has been reported to increase neonatal survival rate by promoting pulmonary development, but it is reported to increase the risk of preterm birth.^[@ref8]^ Further studies are needed to establish a standard therapy to improve the prognosis of severe CDH.

Vascular abnormalities and remodeling caused by endothelial dysfunction is known to occur in patients with PH as part of its pathophysiology.^[@ref9]^ Pharmacotherapies for PH often target the vasoactive mediators, but poor response of patients with CDH to these treatments remains a problem.^[@ref10]^ Accumulating more knowledge regarding the pathophysiology of PH in infants with CDH will have important implications in future therapeutic designs for neonates with severe CDH.

The aim of this study was to describe proteomic profiling in isolated left-sided CDH using umbilical cord serum analyzed via liquid chromatography--tandem mass spectrometry (LC--MS/MS).

MATERIALS AND METHODS
=====================

Patient and sample collection
-----------------------------

Study participants comprised healthy pregnant women who had singleton delivery at term via cesarean section at the Nagoya University Hospital from April 2012 to August 2018. Isolated left-sided CDH cases (CDH, n = 4) and normal healthy controls (Control, n = 4) were matched by gestational age at birth, parity, and sex of babies.

The serum samples from umbilical vein and clinical data of CDH and Control groups were obtained. The specimens were immediately stored in vacuum blood collection tubes at 4°C until isolation. The serum was isolated 16--24 h after blood collection, following which the samples were stored at −80°C.

The study was approved by the Ethics Committee at the Nagoya University Graduate School of Medicine (approval number: 2018-0145). Pre-existing samples and medical records were used. Thus, we provided disclosure of information on the methods of this study and gave participants an opportunity to reject the enrollment in this study, in accordance with the ethical guidelines established by the Japanese Ministry of Health, Labour and Welfare.

Mass spectrometry and data analysis
-----------------------------------

The procedure was performed in accordance with previous reports.^[@ref11],[@ref12]^ The total protein concentration of serum samples was assessed using the bicinchoninic acid assay (Pierce™ BCA Protein Assay kit; Thermo Fisher Scientific Inc., Waltham, MA) in accordance with the manufacturer's instruction. The proteins were trypsin-digested for 16 h at 37°C after reduction with dithiothreitol (final concentration, 5 mM) for 30 min at room temperature and alkylation with iodoacetamide (final concentration, 10 mM) for 60 min at room temperature in the dark. The peptides were analyzed using LC−MS/MS using an Orbitrap Fusion mass spectrometer (Thermo Fisher Scientific Inc.) coupled to an UltiMate3000 RSLC nano-LC system (Dionex Co., Amsterdam, The Netherlands) with a nano-HPLC capillary column, 150 mm × 75 μm i.d (Nikkyo Technos Co., Japan) via a nano-electrospray ion source. Reversed-phase chromatography was performed with a linear gradient (0 min, 5% B; 100 min, 40% B) of solvent A (2% acetonitrile with 0.1% formic acid) and solvent B (95% acetonitrile with 0.1% formic acid) at an estimated flow rate of 300 nL/min. A precursor ion scan was performed with a 400--1600 mass to charge ratio (m/z) prior to MS/MS analysis. Furthermore, tandem MS was performed by isolation at 0.8 Th with quadrupole, high-energy collision dissociation fragmentation with normalized collision energy of 35% and a rapid scan MS analysis in the ion trap. Only precursors with a charge state of 2--6 were sampled for MS2. The dynamic exclusion duration was set to 15 s with a 10 ppm tolerance. The instrument was run in top speed mode with 3-s cycles. The raw data was processed using Proteome Discoverer 1.4 (Thermo Fisher Scientific Inc.) in conjunction with MASCOT search engine, version 2.6.0 (Matrix Science Inc., Boston, MA) for protein identification. Peptides and proteins were identified against the human protein database in UniProt (release 2018_11) with a precursor mass tolerance of 10 ppm and fragment ion mass tolerance of 0.8 Da. Fixed modifications were set for the carbamidomethylation of cysteine, whereas variable modifications were set for the oxidation of methionine. Two missed cleavages by trypsin were allowed.

Protein quantification was performed using the Proteome Discoverer (Thermo Fisher Scientific Inc.), which calculates the peak area of precursor ions on the basis of the top three unique peptides for the given protein.

Proteomic analysis and visualization
------------------------------------

Proteins abundance with fold changes of ≤0.5 or ≥2 in the CDH group compared to with those in the Control group were analyzed.^[@ref13]^ In addition, the following filters were applied: (i) minimum two matched unique peptides were considered,^[@ref14]^ and ii) score \> 35: it is related to the number of peptide sequences that have been identified for a protein.^[@ref15]^ On the basis of these criteria, proteins were detected as differentially expressed proteins (DEPs). Database for Annotation, Visualization and Integrated Discovery (DAVID, <http://david.abcc.ncifcrf.gov>, and version 6.8) was used to analyze DEPs. *Kyoto Encyclopedia of Genes and Genomes* (KEGG, <https://www.genome.jp/kegg/kegg_ja.html>) was used to analyze the enrichment pathways involved in DEPs. Proteomaps were used to show the graphical areas of each protein reflecting the magnitude of the average fold change in DEPs for cases compared with that for controls (<https://www.proteomaps.net/>). Reactome was used to describe the functions and pathways in which proteins were involved (<https://reactome.org/dev/graph-database>). Protein interactome map was used to predict protein·protein interaction analyzed using STRING online database (<https://string-db.org/>). The nodes in the interactome map expressed retrieved data as the results of the neighboring network analysis.

Statistical Analysis
--------------------

Data sets were tested for normality and then analyzed using SPSS ver. 25 for Windows (IBM Corp., Armonk, NY). Group data were presented as median \[range\] and compared using Mann-Whitney *U* test. Statistically significant difference was set at a p value of \< 0.05.

RESULTS
=======

All patients in the CDH group were treated for PH with high-frequency oscillatory ventilation and inhaled nitric oxide. Two patients required further extracorporeal membrane oxygenation therapy because of severe CDH. One patient died 7 days after birth because of severe PH. Several characteristics of the Control group (n = 4) were matched, including gestational age at birth. Most of the maternal and neonatal clinical characteristics were similar, such as maternal age, birth weight, and umbilical arterial blood pH ([Table 1](#table1){ref-type="table"}). Only Apgar scores at 1 (5 \[5--6\] vs 9 \[9--9\]; *p* \< 0.001) and 5 (3.5 \[3--8\] vs 10. \[9--10\]; *p* = 0.005) min were the significantly different characteristic between the CDH and Control groups.

###### 

Maternal characteristics and neonate outcomes

                                    **CDH (n = 4)**         **Control (n = 4)**     ***p*** **value\***
  --------------------------------- ----------------------- ----------------------- ---------------------
  Maternal age (year)               36.0 \[29.9 -- 40.3\]   31.1 \[25.1 -- 38.2\]   0.34
  Parity (Primiparous/Total)        2/4 (50.0%)             2/4 (50.0%)             
  Gestational age at birth (week)   37.9 \[37.4 -- 39.9\]   38.4 \[38.1 -- 38.7\]   
  Outcomes of neonates                                                              
  Sex (Male/Total)                  2/4 (50.0%)             2/4 (50.0%)             
  Birth weight (g)                  3188 \[2765 -- 3324\]   2939 \[2880 -- 3236\]   0.68
  Apgar score 1 min                 5 \[5 -- 6\]            9 \[9 -- 9\]            \< 0.001
  Apgar score 5 min                 3.5 \[3 -- 8\]          10 \[9 -- 10\]          0.005
  Umbilical blood pH                7.34 \[7.31 -- 7.44\]   7.32 \[7.29 -- 7.34\]   0.49

Data is shown as median \[range\] or number (%).

\*Mann-Whitney's *U* test was used.

The 697 proteins identified via LC--MS/MS were analyzed using the MASCOT program, and 98 of these were found to be DEPs. Of these DEPs, the complement C1q (C1q) subcomponent showed the highest fold change, followed by complement C5 (C5) ([Table 2](#table2){ref-type="table"}).

###### 

DEPs

  Accession    Description                                                        Fold-change   *p* value\*
  ------------ ------------------------------------------------------------------ ------------- -------------
  P02746       Complement C1q subcomponent subunit B                              41.520        0.114
  P01031       Complement C5                                                      23.591        0.200
  Q15063       Periostin                                                          20.247        0.029
  P60709       Actin, cytoplasmic 1                                               17.934        0.029
  P08603       Complement factor H                                                13.429        0.057
  P0CG38       POTE ankyrin domain family member I                                12.254        0.029
  P68133       Actin, alpha skeletal muscle                                       11.338        0.029
  P07996       Thrombospondin-1                                                   10.122        0.057
  P09871       Complement C1s subcomponent                                        9.055         0.057
  Q6S8J3       POTE ankyrin domain family member E                                8.033         0.057
  Q03591       Complement factor H-related protein 1                              7.897         0.114
  P01871       Immunoglobulin heavy constant mu                                   7.883         0.057
  P00736       Complement C1r subcomponent                                        6.679         0.114
  Q15485       Ficolin-2                                                          6.081         0.343
  P49747       Cartilage oligomeric matrix protein                                5.024         0.114
  P05155       Plasma protease C1 inhibitor                                       4.506         0.057
  P07359       Platelet glycoprotein Ib alpha chain                               4.456         0.057
  Q14520       Hyaluronan-binding protein 2                                       4.437         0.200
  Q08380       Galectin-3-binding protein                                         4.332         0.114
  P0DOX6       Immunoglobulin mu heavy chain                                      4.216         0.114
  P04180       Phosphatidylcholine-sterol acyltransferase                         4.205         0.114
  P07358       Complement component C8 beta chain                                 4.003         0.114
  P40197       Platelet glycoprotein V                                            3.988         0.486
  P00734       Prothrombin                                                        3.987         0.029
  P02743       Serum amyloid P-component                                          3.940         1.000
  P35443       Thrombospondin-4                                                   3.908         0.200
  P36980       Complement factor H-related protein 2                              3.875         0.114
  P00747       Plasminogen                                                        3.800         0.114
  Q06033       Inter-alpha-trypsin inhibitor heavy chain H3                       3.747         0.200
  A0A0B4J1U7   Immunoglobulin heavy variable 6-1                                  3.715         0.029
  A0A0C4DH67   Immunoglobulin kappa variable 1-8                                  3.567         0.029
  P00742       Coagulation factor X                                               3.412         0.200
  P36955       Pigment epithelium-derived factor                                  3.295         0.057
  A0A075B6S5   Immunoglobulin kappa variable 1-27                                 3.260         0.029
  Q969T7       7-methylguanosine phosphate-specific 5'-nucleotidase               3.177         0.057
  Q9Y566       SH3 and multiple ankyrin repeat domains protein 1                  3.110         0.686
  P01011       Alpha-1-antichymotrypsin                                           2.986         0.057
  P02751       Fibronectin                                                        2.979         0.343
  P07225       Vitamin K-dependent protein S                                      2.836         0.486
  P04004       Vitronectin                                                        2.730         0.200
  P00748       Coagulation factor XII                                             2.724         0.114
  P10909       Clusterin                                                          2.710         0.057
  A0A087WW87   Immunoglobulin kappa variable 2-40                                 2.701         0.114
  A0A075B6P5   Immunoglobulin kappa variable 2-28                                 2.666         0.114
  P0C0L4       Complement C4-A                                                    2.657         0.200
  P0C0L5       Complement C4-B                                                    2.657         0.200
  P00450       Ceruloplasmin                                                      2.635         0.114
  Q04756       Hepatocyte growth factor activator                                 2.557         1.000
  P04275       von Willebrand factor                                              2.547         1.000
  P62937       Peptidyl-prolyl cis-trans isomerase A                              2.541         1.000
  P29622       Kallistatin                                                        2.521         0.057
  O75636       Ficolin-3                                                          2.472         0.343
  P01024       Complement C3                                                      2.470         0.114
  P15169       Carboxypeptidase N catalytic chain                                 2.440         0.029
  Q96IY4       Carboxypeptidase B2                                                2.433         1.000
  P06310       Immunoglobulin kappa variable 2-30                                 2.297         0.200
  Q15848       Adiponectin                                                        2.288         0.343
  P26927       Hepatocyte growth factor-like protein                              2.284         0.114
  P07357       Complement component C8 alpha chain                                2.263         0.486
  A0A075B6I9   Immunoglobulin lambda variable 7-46                                2.256         0.343
  P04196       Histidine-rich glycoprotein                                        2.249         0.114
  P02042       Hemoglobin subunit delta                                           2.228         0.029
  P04278       Sex hormone-binding globulin                                       2.220         0.057
  O75420       PERQ amino acid-rich with GYF domain-containing protein 1          2.209         0.114
  P48740       Mannan-binding lectin serine protease 1                            2.209         0.486
  P05109       Protein S100-A8                                                    2.189         0.200
  P19823       Inter-alpha-trypsin inhibitor heavy chain H2                       2.142         0.343
  P02656       Apolipoprotein C-III                                               2.138         0.200
  A0A0B4J1Y8   Immunoglobulin lambda variable 9-49                                2.059         0.200
  P05452       Tetranectin                                                        2.051         0.114
  P02760       Protein AMBP                                                       2.018         0.114
  A0A075B6S6   Immunoglobulin kappa variable 2D-30                                2.018         0.114
  P01703       Immunoglobulin lambda variable 1-40                                0.490         0.343
  P22570       NADPH:adrenodoxin oxidoreductase, mitochondrial                    0.489         0.486
  Q12805       EGF-containing fibulin-like extracellular matrix protein 1         0.460         0.886
  A0A075B6J9   Immunoglobulin lambda variable 2-18                                0.453         0.486
  P43251       Biotinidas                                                         0.429         0.343
  P04114       Apolipoprotein B-100                                               0.423         1.000
  P22105       Tenascin-X                                                         0.405         0.200
  P00739       Haptoglobin-related protein                                        0.390         0.343
  P04406       Glyceraldehyde-3-phosphate dehydrogenase                           0.367         1.000
  P35527       Keratin, type I cytoskeletal 9                                     0.365         0.445
  P01876       Ig alpha-1 chain C region                                          0.357         0.043
  P01817       Immunoglobulin heavy variable 2-5                                  0.320         0.343
  P01034       Cystatin-C                                                         0.320         0.200
  P80108       Phosphatidylinositol-glycan-specific phospholipase D               0.317         0.886
  P46199       Translation initiation factor IF-2, mitochondrial                  0.300         0.200
  Q6EMK4       Vasorin                                                            0.298         0.114
  Q9NZP8       Complement C1r subcomponent-like protein                           0.284         0.200
  P12259       Coagulation factor V                                               0.273         0.886
  P13671       Complement component C6                                            0.270         0.200
  P05543       Thyroxine-binding globulin                                         0.210         0.114
  P27361       Mitogen-activated protein kinase 3                                 0.204         0.057
  P35542       Serum amyloid A-4 protein                                          0.157         0.057
  Q96QT4       Transient receptor potential cation channel subfamily M member 7   0.123         0.114
  P12036       Neurofilament heavy polypeptide                                    0.106         0.486
  Q86YZ3       Hornerin                                                           0.023         0.200
  P33151       Cadherin-5                                                         0.011         1.000

\*Mann-Whitney's *U* test was used.

In the pathway enrichment analysis, the complement and coagulation cascades showed the highest significance (*p* = 2.4 × 10^−26^; [Fig. 1A](#fig1){ref-type="fig"}). In addition, enrichment analysis of the Gene Ontology terms for a biological process showed complement activation of the classical pathway as significant (*p* = 1.3 × 10^−29^; [Fig. 1B](#fig1){ref-type="fig"}). Nine of the 20 pathways, such as complement activation, complement activation classical pathway, and platelet degranulation, were related to the complement and coagulation cascades ([Fig. 1B](#fig1){ref-type="fig"}). The Proteomap showed the involvement of complement and coagulation cascades (Figs. 1C--E). In Reactome, several protein interactions were expressed in the immune system in the CDH group ([Fig. 1F](#fig1){ref-type="fig"}). Furthermore, the Protein Interactome map showed that the complement and coagulation factors were present in CDH ([Fig. 1G](#fig1){ref-type="fig"}). \[[Figure 1](#fig1){ref-type="fig"}\]

![Proteomic analysis of umbilical cord of neonates with congenital diaphragmatic hernia (CDH) and controls\
A. Pathway enrichment analysis. B. Gene Ontology enrichment analysis for biological process. Top 20 proteins are shown. C--E. Proteomaps. Low (C), middle (D), and high levels (E) of Gene Ontology annotations. Each colored area reflects the magnitude of the average fold change with respect to protein expression for cases compared with that for controls. F. Reactome map. It shows that DEPs are enriched in the immune system in patients with CDH. G. Protein Interactome map. The nodes contain several complement factors including C1QB, C3, C4A, C4B and C5.](2186-3326-82-0345-g001){#fig1}

DISCUSSION
==========

This is the first study to describe the proteomic profiling of umbilical cord serum in isolated left-sided CDH, using LC--MS/MS analysis. In the present study, the complement and coagulation cascades, such as C1q subcomponent and C5, were enriched in the umbilical cord serum of CDH cases. To the best of our knowledge, there are only two studies on proteomic profiling of human CDH, these studies have used with amniotic fluid^[@ref16]^ and exhaled breath condensate.^[@ref17]^ In addition, such investigations have been performed using the lung tissue^[@ref18]^ and tracheal fluid^[@ref19]^ of animal models. However, inconsistent results have been obtained possibly because of different tissues or different species. In the amniotic fluid of human CDH cases, no specific protein spot was revealed.^[@ref16]^ Conversely, a number of proteins in the exhaled breath condensates were suggested as biomarkers of CDH.^[@ref17]^ In animal CDH models, myosin light chain was absent in rat lung tissue,^[@ref18]^ and several pathways, including those involved in cell proliferation, were reported to be altered in the ovine tracheal fluid.^[@ref19]^ These factors are considered to be associated with pulmonary hypoplasia in CDH. The present study revealed a new finding that the complement and coagulation cascades were enriched in the umbilical cord serum of CDH cases. Moreover, complement factors, including C1q subcomponent and C5, were identified to be DEPs. Involvement of the complement factors in CDH remains to be investigated. In a previous report with ovine CDH model, complement and coagulation cascades were shown as enriched pathways in CDH lung.^[@ref19]^ Moreover, complement pathway activation is known to contribute to PH.^[@ref20]^ In pediatric PH, evaluation of the complement factors C3 and C4 is recommended.^[@ref5]^ In the lung tissues of rat PH models, the complement and coagulation cascades were enriched^[@ref21]^ and C1q expression was increased.^[@ref22]^ Furthermore, C1q was reported to cause hypertensive arterial remodeling and smooth muscle hyperplasia via β-catenin signaling.^[@ref23]^ It has been demonstrated that the complement pathway has a pathological role in the development of PH and is a possible therapeutic target for PH.^[@ref24]^ These findings suggest that the complement pathway might also be involved in the pathophysiology of PH in CDH. In this study, all CDH cases developed PH and half of them exhibited severe PH. In the present study, umbilical serum was used for analyses. Given the fact that serum contains several components from pulmonary vessels, we propose that umbilical serum could be superior to bronchioalveolar secretions in amniotic fluid and exhaled breath condensate in predicting the subsequent PH at birth. Whereas, results from the latter may be affected by the fetus maturity and treatment after birth.

This study has some limitations. First, samples from a single facility were analyzed. Second, the circulating proteins might not reflect the exact processes occurring in the lungs or pulmonary arterial walls. Third, we could not investigate the maternal serum samples. However, the effect of maternal background could be ignored because the participants did not have any other complications. Therefore, further studies with a larger sample size and analyses based on CDH severity are necessary.

CONCLUSION
==========

This is the first study on CDH with proteomic profiling of umbilical cord serum using LC--MS/MS analysis. The complement and coagulation cascades may be associated with the pathophysiology of PH in CDH. This finding may help in the development of new therapeutic strategies, although further investigations are required.
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